Available Locations Critical Document Checklist SAE List my Site 20396 Patients Training Log Generate Document(Florence) my Site 20396 Training Monitoring Calendar CRF Summary A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) (D967UC00001)
Disease Types: Breast Cancer Research
-Advanced or metastatic HER 2+ breast cancer with measurable disease and no prior chemotherapy or HER 2+ targeted therapy in the advanced or metastatic setting.
-No: HIV, active Hepatitis B or Hepatitis C; myocardial infarction within past 6 months, symptomatic congestive heart failure (NYHA Class II – IV); clinically significant pulmnary disorder such as severe asthma or chronic obstructive pulmonary disorder (COPD), prior pneumonectomy; history of arrhythmia which is symptomatic and requires treatment such as uncontrolled atrial fibrillation,asymptomatic, sustained ventricular tachycardia (if controlled by medications or pacemaker allowed); history of interstitial lung disease (ILD)/pneumonits that required steriods or current or suspected ILD/pneumonitis.
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach (Princess Anne)